French biotech DBV Technologies SA is starting to build up its commercial presence in the U.S., where it expects to launch its transdermal food allergy therapy Viaskin Peanut first in several years’ time.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?